ORGANIZATION

Ishikawa Pharmacist Group Makes Direct Plea to Health Minister for Ad-Hoc Lifting of Shipment Curbs

By Takashi Ebisawa January 19, 2024

Ishikawa Pharmaceutical Association President Keiji Nakamori
Ishikawa Pharmaceutical Association President Keiji Nakamori

The Ishikawa Pharmaceutical Association on January 18 urged Health Minister Keizo Takemi that emergency measures be taken to lift the shipment restrictions of certain medicines within the quake-hit prefecture.

Keiji Nakamori, president of the association, met Mr Takemi in Kanazawa to directly make this request as the minister visited the Ishikawa capital in the aftermath of the massive earthquake on New Year’s Day.

Mr Nakamori told Jiho that he made the plea in order to secure the necessary drugs in areas affected by the disaster. In response, Mr Takemi instructed officials accompanying him to convey this request to the ministry headquarters, according to Mr Nakamori.

An association of drug distributors in Ishikawa Prefecture and the Federation of Japan Pharmaceutical Wholesalers Association (JPWA) on January 9 had made a joint request to the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ) to prioritize supplies of products under shipment controls and other necessary medicines to the Hokuriku central Japan area. However, the shortage in medicines has not yet been resolved for pharmacists dispensing drugs at the frontline, including Mr Nakamori himself.

Also, as secondary evacuations progress, from the most affected areas to Kanazawa and other regions, the shortage of drugs is becoming an issue for not only the hardest-hit zones but the whole of the prefecture. The Ishikawa Pharmaceutical Association thus asked the minister for the execution of bolder measures.

Speaking to Jiho, Mr Nakamori emphasized, “Wholesalers are making requests to manufacturers, but the situation has not changed at all between before and after the earthquake.”

Mr Nakamori also told the minister that the pharmacy outlets he runs have reported that they are currently not seeing deliveries for 10 medicines, including the expectorant carbocysteine, antipyretic analgesic Calonal (acetaminophen), and montelukast, a treatment for bronchial asthma and allergic rhinitis.

Related Article

ORGANIZATION

By Ken Yoshino

Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…

By Philip Carrigan

For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…